KalVista Pharmaceuticals/KALV

$14.01

-5.72%
-
1D1W1MYTD1YMAX

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecule protease inhibitors for diseases with unmet need. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting the disease hereditary angioedema (HAE). The Company is developing sebetralstat as an oral on-demand therapy for HAE attacks and has achieved target enrollment for the phase 3 KONFIDENT clinical trial. The Company is also conducting preclinical development on oral Factor XIIa (Factor XIIa) inhibitor program, which is advancing to provide the next generation of HAE therapeutics. It is also focused on development of oral plasma kallikrein inhibitors for HAE and Factor XIIa inhibitors for HAE and other indications. Plasma kallikrein is a serine protease enzyme that is a key mediator of inflammation and edema.
Ticker
KALV
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
CEO
Thomas Crockett
Employees
118
Headquarters
Cambridge, United States

KALV Metrics

BasicAdvanced
$513.54M
Market cap
-
P/E ratio
-$3.06
EPS
0.94
Beta
-
Dividend rate

What the Analysts think about KALV

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 5 analysts.
125.55% upside
High $39.00
Low $24.00
$14.01
Current price
$31.60
Average price target

KALV Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q2 24
QoQ growth
Revenue
$0
-
Net income
$-27.6M
9.09%
Profit margin
0%
-

KALV Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 1.73%
QuarterlyAnnual
Q3 23
Q4 23
Q1 24
Q2 24
Q3 24
Actual
-$0.75
-$0.77
-$0.74
-$0.80
-
Expected
-$0.99
-$0.94
-$0.86
-$0.79
-$0.77
Surprise
-23.86%
-17.94%
-13.79%
1.73%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell KalVista Pharmaceuticals stock

Buy or sell KalVista Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing